The phase III Clarity AD clinical trial of lecanemab, an amyloid-targeting antibody, showed a small clinical benefit in people with Alzheimer disease. However, several questions remain regarding the true clinical relevance, safety and accessibility of lecanemab in this patient population.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Evaluating the effect of rapamycin treatment in Alzheimer’s disease and aging using in vivo imaging: the ERAP phase IIa clinical study protocol
BMC Neurology Open Access 04 April 2024
-
Oligodendrocyte progenitor cells in Alzheimer’s disease: from physiology to pathology
Translational Neurodegeneration Open Access 14 November 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2212948 (2022).
Ackley, S. F. et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ 372, n156 (2021).
Gleason, A., Ayton, S. & Bush, A. I. Unblinded by the light: amyloid-related imaging abnormalities in Alzheimer’s clinical trials. Eur. J. Neurol. 28, e1 (2021).
Center for Drug Evaluation and Research. Aduhelm (aducanumab) FDA statistical review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000StatR.pdf (2021).
Andrews, J. S. et al. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer’s disease clinical trials. Alzheimers Dement. (N.Y.) 5, 354–363 (2019).
Lansdall, C. J. et al. Establishing clinically meaningful change on outcome assessments frequently used in trials of mild cognitive impairment due to Alzheimer’s disease. J. Prev. Alzheimers Dis. https://doi.org/10.14283/jpad.2022.102 (2022).
Piller, C. Second death linked to potential antibody treatment for Alzheimer’s disease. Science https://doi.org/10.1126/science.adf9701 (2022).
Nestor, S. M. et al. Ventricular enlargement as a possible measure of Alzheimer’s disease progression validated using the Alzheimer’s disease neuroimaging initiative database. Brain 131, 2443–2454 (2008).
Silbert, L. C. et al. Changes in premorbid brain volume predict Alzheimer’s disease pathology. Neurology 61, 487–492 (2003).
Canevelli, M. et al. “Real world” eligibility for aducanumab. J. Am. Geriatr. Soc. 69, 2995–2998 (2021).
Acknowledgements
M.T. is a full-time employee at the intramural programme of the National Institute on Aging (Baltimore, MD, USA). R.H. is supported by the National Institute for Health Research University College Hospital London Biomedical Research Centre (London, UK).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Thambisetty, M., Howard, R. Lecanemab trial in AD brings hope but requires greater clarity. Nat Rev Neurol 19, 132–133 (2023). https://doi.org/10.1038/s41582-022-00768-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-022-00768-w
This article is cited by
-
Evaluating the effect of rapamycin treatment in Alzheimer’s disease and aging using in vivo imaging: the ERAP phase IIa clinical study protocol
BMC Neurology (2024)
-
Oligodendrocyte progenitor cells in Alzheimer’s disease: from physiology to pathology
Translational Neurodegeneration (2023)
